Peregrine Pharma (PPHM) Misses Q3 EPS by 1c

March 13, 2017 4:08 PM EDT

Peregrine Pharma (NASDAQ: PPHM) reported Q3 EPS of ($0.04), $0.01 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $10.75 million versus the consensus estimate of $14 million.

GUIDANCE:

Peregrine Pharma sees FY2017 revenue of $60-65 million.

For earnings history and earnings-related data on Peregrine Pharma (PPHM) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance

Related Entities

Earnings